Journal
HEART FAILURE CLINICS
Volume 7, Issue 3, Pages 299-+Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.hfc.2011.03.004
Keywords
Cardiotoxicity; Hypertension; Heart failure; Cancer
Categories
Ask authors/readers for more resources
Targeted antiangiogenic cancer therapies have revolutionized the treatment of highly vascularized cancers such as metastatic renal cell carcinoma and gastrointestinal stromal tumors. Such agents act by inhibiting the actions of proangiogenic growth factors and their receptor tyrosine kinases, which are known to be overexpressed in cancer. However, these factors also play an important role in normal cardiovascular physiology. This article summarizes the incidences of cardiovascular toxicities (namely hypertension and heart failure) associated with the most commonly used antiangiogenic therapies, and then presents data from preclinical and clinical studies to provide some insight into the underlying molecular mechanisms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available